$NRIX News

What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

CORRECTION: Nurix Therapeutics Q3 EPS $4.73 Beats $3.98 Estimate, Sales $673.064M Beat $411.481M Estimate

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration

Nurix Therapeutics (NASDAQ:NRIX) Breakout Setup Backed by Technical Rating of 8 and Setup Rating of 9

Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NRIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics to Participate in Upcoming September Investor Conferences